Synlogic (SYBX) Q3 2025 earnings summary

Executive summary

• Discontinued lead Phase 3 clinical trial (Synpheny-3 for PKU) in February 2024 after internal review indicated it was unlikely to meet its primary endpoint; no safety concerns cited.

• Corporate restructuring initiated, reducing workforce to one full-time employee and engaging consultants to support strategic review and business operations.

• Current strategy is focused on pursuing strategic alternatives, including a potential merger, sale, or partnerships.

Financial highlights

• Net loss of $2.3 million for Q3 2025, compared to $0.1 million in Q3 2024; net loss of $2.5 million for the nine months ended September 30, 2025, versus $22.6 million for the same period in 2024.

• Operating expenses for Q3 2025: $0.01 million in R&D, $0.8 million in G&A, $0.2 million in restructuring; significant reductions from prior year.

• Cash and cash equivalents of $15.6 million as of September 30, 2025, down from $19.8 million at year-end 2024.

• Accumulated deficit of $444.2 million as of September 30, 2025.

Outlook and guidance

• Current cash and cash equivalents expected to fund operations at current levels for at least the next 12 months from the filing date.

• Expenses anticipated to remain stable in the near term as the company continues to evaluate strategic alternatives.